Betahistine, tablets 24 mg 30 pcs

Agonist of H₁-receptors of the inner ear vessels and antagonist of H₃-receptors of the vestibular nucleiCNS. By direct agonist effect on H₁-receptors of inner ear vessels and also indirectly through the effect on H₃-receptors it improves microcirculation and capillary permeability, normalizes endolymph pressure in labyrinth and cochlea, increases blood flow in basilar artery.

It has a pronounced central effect, being an inhibitor of H₃-receptors of the vestibular nerve nuclei. It improves conduction in neurons of vestibular nuclei at brainstem level.

The clinical manifestation of the above properties is reduction of the frequency and intensity of dizziness, reduction of tinnitus, improvement of hearing if it is reduced.

Indications

treatment and prevention of vestibular vertigo of various origins;
syndromes including dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting;
Meniere’s disease or syndrome.

Pharmacological effect

An agonist of H1 receptors in the vessels of the inner ear and an antagonist of H3 receptors in the vestibular nuclei of the central nervous system. Through a direct agonistic effect on H1 receptors of the vessels of the inner ear, as well as indirectly through an effect on H3 receptors, it improves microcirculation and capillary permeability, normalizes endolymph pressure in the labyrinth and cochlea, and increases blood flow in the basilar artery.

It has a pronounced central effect, being an inhibitor of H3 receptors in the nuclei of the vestibular nerve. Improves conductivity in neurons of the vestibular nuclei at the level of the brain stem.

The clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in tinnitus, and an improvement in hearing if it is reduced.

Special instructions

Patients with a history of gastric or duodenal ulcers, pheochromocytoma or bronchial asthma should be prescribed the drug under regular medical supervision.

Impact on the ability to drive vehicles and operate machinery

Betahistine does not have a sedative effect and does not affect the ability to drive a car or engage in activities that require rapid psychomotor reactions.

Active ingredient

Betahistine

Composition

1 tablet contains:

Active substance: betahistine dihydrochloride 24 mg;

Excipients: MCC; lactose (milk sugar); citric acid monohydrate; colloidal silicon dioxide (Aerosil); crospovidone; talc; magnesium stearate.

Contraindications

hypersensitivity to any of the components of the drug;
lactose intolerance;
lactase deficiency or glucose-galactose malabsorption;
age under 18 years;
pregnancy;
lactation period.

With caution:

peptic ulcer of the stomach and duodenum (history);
pheochromocytoma;
bronchial asthma.

Side Effects

Gastrointestinal disorders, allergic reactions of the skin (skin rash, itching, urticaria), Quincke’s edema.

Interaction

There are no known cases of interaction or incompatibility with other drugs.

Overdose

Symptoms: nausea, vomiting, convulsions.

Treatment: gastric lavage, taking activated carbon, symptomatic therapy.

Storage conditions

Store in a dry place, out of reach of children, protected from light, at a temperature not exceeding 25°C.

Shelf life

2 years

Manufacturer

Ozon, Russia